Globus Medical (GMED) reported $745.34 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 18.4%. EPS of $0.86 for the same period compares to $0.75 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $741.7 million, representing a surprise of +0.49%. The company delivered an EPS surprise of +13.16%, with the consensus EPS estimate being $0.76.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Globus Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- International: $144.56 million compared to the $140.52 million average estimate based on three analysts. The reported number represents a change of +11% year over year.
- Geographic Revenues- United States: $600.78 million compared to the $586.71 million average estimate based on three analysts. The reported number represents a change of +20.3% year over year.
- Net Sales by Product Category- Enabling Technologies: $35.16 million versus the five-analyst average estimate of $37.43 million. The reported number represents a year-over-year change of -4.4%.
- Net Sales by Product Category- Musculoskeletal Solutions: $710.18 million compared to the $679.67 million average estimate based on five analysts. The reported number represents a change of +19.8% year over year.
View all Key Company Metrics for Globus Medical here>>>
Shares of Globus Medical have returned -7.8% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Globus Medical, Inc. (GMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
